STOCK TITAN

Atea Pharmaceuticals director sells 22,619 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Atea Pharmaceuticals, Inc. director Bruno Lucidi exercised options to acquire 21,628 shares on November 17, 2026 at an exercise price of $1.24 per share, then sold 6,741 shares at a weighted-average price of $4.0335. On November 19, 2026, he exercised options to acquire 53,372 shares at $1.24 per share and sold 22,619 shares at a weighted-average $3.9445. The sales were reported as paying option exercise costs and serving tax-planning purposes; no Rule 10b5-1 plan is reported.

Insider Lucidi Bruno
Role Director
Sold 29,360 shs ($116K)
Approx. gross sale proceeds $116K
Approx. exercise cost $93K
Share of Position Sold 13.5%
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F3 53,372 $0.00 $0.00
Exercise Common Stock 53,372 $1.24 $66K
Sale Common Stock F2 22,619 $3.9445 $89K
Exercise Stock Option (Right to Buy) F3 21,628 $0.00 $0.00
Exercise Common Stock 21,628 $1.24 $27K
Sale Common Stock F1 6,741 $4.0335 $27K
Holdings After Transaction: Stock Option (Right to Buy) — 0 options (Direct); Common Stock — 187,990 shares (Direct)
Holdings Before and After: Stock Option (Right to Buy), 75,000 to 0 options (Direct); Common Stock, 142,350 to 187,990 shares (Direct)
Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (3)
  1. F1. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.10. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. F2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.91 to $3.97. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3. The option is fully vested and exercisable.
Shares acquired through option exercise 21,628 shares November 17, 2026
Exercise price $1.24 per share Options exercised November 17, 2026
Shares sold 6,741 shares November 17, 2026
Weighted-average sale price $4.0335 per share November 17, 2026; sale prices ranged from $4.00 to $4.10 per share
Shares acquired through option exercise 53,372 shares November 19, 2026
Exercise price $1.24 per share Options exercised November 19, 2026
Shares sold 22,619 shares November 19, 2026
Weighted-average sale price $3.9445 per share November 19, 2026; sale prices ranged from $3.91 to $3.97 per share
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
exercise price financial
"pay the exercise price of the options"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested and exercisable financial
"The option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Atea Pharmaceuticals director Bruno Lucidi report for November 17, 2026?

On November 17, 2026, Bruno Lucidi exercised options to acquire 21,628 shares at $1.24 per share and sold 6,741 shares at a weighted-average $4.0335 per share. The sale prices ranged from $4.00 to $4.10 per share. The sales were reported as paying option exercise costs and serving tax-planning purposes; no Rule 10b5-1 plan is reported.

What did Atea Pharmaceuticals director Bruno Lucidi report for November 19, 2026?

On November 19, 2026, Bruno Lucidi exercised options to acquire 53,372 shares at $1.24 per share and sold 22,619 shares at a weighted-average $3.9445 per share. The sale prices ranged from $3.91 to $3.97 per share. The sales were reported as paying option exercise costs and serving tax-planning purposes; no Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lucidi Bruno

(Last)(First)(Middle)
225 FRANKLIN STREET
SUITE 2100

(Street)
BOSTON MASSACHUSETTS 02110

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026M21,628A$1.24163,978D
Common Stock11/17/2026S6,741D$4.0335(1)157,237D
Common Stock11/19/2026M53,372A$1.24210,609D
Common Stock11/19/2026S22,619D$3.9445(2)187,990D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.2411/17/2026M21,628 (3)12/08/2026Common Stock21,628$053,372D
Stock Option (Right to Buy)$1.2411/19/2026M53,372 (3)12/08/2026Common Stock53,372$00D
Explanation of Responses:
1. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.10. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.91 to $3.97. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The option is fully vested and exercisable.
Remarks:
All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.
/s/ Andrea Corcoran, as Attorney-in-Fact for Bruno Lucidi11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading